IV.8 Bone disease
Source Information
April 2002, Volume17 Supplement: 4Pages 43To 48 -Permalink
Abstract
Guidelines
A. All kidney‐transplanted patients should undergo a systematic evaluation of their skeletal status, including pre‐transplant history of renal osteodystrophy, history of fractures and plasma concentrations of calciotropic hormones and other parameters, and if possible measurement of bone mineral density (BMD).
(Evidence level C)
B. Glucocorticoid therapy should be given at the lowest possible dosage. As long as patients are receiving steroids, vitamin D treatment (ergocalciferol or 1,25‐dihydroxyvitamin D) is highly recommended.
(Evidence level B)
C. Optimal prevention of bone disease by vitamin D treatment, sufficient calcium intake, sex hormone substitution and appropriate use of thiazide diuretics should be considered in all transplant patients.
(Evidence level C)
D. In established osteopenia, bisphosphonate treatment should be considered despite limited information in transplant recipients.
(Evidence level C)
E. Persistent tertiary hyperparathyroidism should be observed for 1 year after transplantation whenever possible to allow for a spontaneous involution.
(Evidence level C)
F. In patients with GFR <50 ml/min after transplantation, uraemic osteodystrophy should be prevented.
(Evidence level C)